• Income Statement
• Balance Sheet
• Cash Flow
• Ratios
• Market Data
• Valuation

	BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH)
	Q2-CY2026	Q1-CY2026	Q4-CY2025	Q3-CY2025	Q2-CY2025	Q1-CY2025	Q4-CY2024	Q3-CY2024	Q2-CY2024	Q1-CY2024	Q4-CY2023	Q3-CY2023	Q2-CY2023	Q1-CY2023	Q4-CY2022	Q3-CY2022	Q2-CY2022	Q1-CY2022	Q4-CY2021	Q3-CY2021	Q2-CY2021	Q1-CY2021	Q4-CY2020	Q3-CY2020	Q2-CY2020	Q1-CY2020	Q4-CY2019	Q3-CY2019	Q2-CY2019	Q1-CY2019	Q4-CY2018	Q3-CY2018	Q2-CY2018	Q1-CY2018	Q4-CY2017	Q3-CY2017	Q2-CY2017	Q1-CY2017	Q4-CY2016	Q3-CY2016	Q2-CY2016	Q1-CY2016	Q4-CY2015	Q3-CY2015	Q2-CY2015	Q1-CY2015	Q4-CY2014	Q3-CY2014	Q2-CY2014
Balance Sheet Date			2025-Dec-31	2025-Sep-30	2025-Jun-30	2025-Mar-31	2024-Dec-31	2024-Sep-30	2024-Jun-30	2024-Mar-31	2023-Dec-31								2021-Dec-31	2021-Sep-30	2021-Jun-30	2021-Mar-31	2020-Dec-31	2020-Sep-30	2020-Jun-30	2020-Mar-31	2019-Dec-31	2019-Sep-30	2019-Jun-30	2019-Mar-31	2018-Dec-31	2018-Sep-30
Fiscal Period			Q4-FY2025	Q3-FY2025	Q2-FY2025	Q1-FY2025	Q4-FY2024	Q3-FY2024	Q2-FY2024	Q1-FY2024	Q4-FY2023								Q4-FY2021	Q3-FY2021	Q2-FY2021	Q1-FY2021	Q4-FY2020	Q3-FY2020	Q2-FY2020	Q1-FY2020	Q4-FY2019	Q3-FY2019	Q2-FY2019	Q1-FY2019	Q4-FY2018	Q3-FY2018
Total Assets			786$	784$	905$	13,799$	862$	1,635$	667$	640$	638$				734$				11,145$	27,375$	27,405$	31,955$	39,865$	39,865$	42,818$	51,365$	58,895$	52,894$	46,932$	40,970$	35,127$	29,400$			20,908$
Total Current Assets			786$	784$	905$	13,799$	862$	1,635$	667$	640$	638$				734$				11,145$	27,375$	27,405$	31,955$	39,865$	39,865$	42,818$	51,365$	58,895$	52,894$	46,932$	40,970$	35,127$	29,400$			20,908$
Cash and Cash Equivalents			786$	784$	905$	13,799$	862$	1,635$	667$	640$	638$				734$				11,105$	27,305$	27,305$	31,835$	39,865$	39,865$	39,865$	46,865$	52,895$	46,932$	40,970$	35,120$	29,392$	23,888$	23,881$	18,825$	14,325$	14,325$
Receivables
Other Current Assets
Assets Held for Sale in Short Term
Total Noncurrent Assets			0$	0$	0$	0$	0$	0$	0$	0$	0$				0$				0$	0$	0$	0$	0$	0$	0$	0$	0$	0$	0$	0$	0$	0$			0$
Goodwill
Other Intangible Assets
Physical Assets
Other Noncurrent Assets
Assets Held for Sale in Long Term
Total Liabilities			619,329$	500,722$	384,928$	275,041$	2,302,454$	2,180,067$	2,065,075$	1,950,683$	1,819,868$				1,348,011$				873,008$	768,537$	654,707$	536,942$	399,773$	277,208$	162,239$	44,076$	11,587$	4,540$	5,015$	6,775$	5,323$	5,465$			12,706$
Total Current Liabilities			619,329$	500,722$	384,928$	275,041$	2,302,454$	2,180,067$	2,065,075$	1,950,683$	1,819,868$				1,348,011$				873,008$	768,537$	654,707$	536,942$	399,773$	277,208$	162,239$	44,076$	11,587$	4,540$	5,015$	6,775$	5,323$	5,465$			12,706$
Accounts Payable
Short Term Debt
Short Term Capital Lease Obligations
Other Current Liabilities
Total Noncurrent Liabilities			0$	0$	0$	0$	0$	0$	0$	0$	0$				0$				0$	0$	0$	0$	0$	0$	0$	0$	0$	0$	0$	0$	0$	0$			0$
Long Term Debt
Long Term Capital Lease Obligations
Other Noncurrent Liabilities
Total Equity			(618,543$)	(499,938$)	(384,023$)	(261,242$)	(2,301,592$)	(2,178,432$)	(2,064,408$)	(1,950,043$)	(1,819,230$)	(1,704,820$)	(1,591,213$)	(1,477,282$)	(1,347,277$)				(861,863$)	(741,162$)	(627,302$)	(504,987$)	(359,908$)	(237,343$)	(119,421$)	7,289$	47,308$	48,354$	41,917$	34,195$	29,804$	23,935$	16,344$	14,097$	8,202$
Equity to Minority
Equity to Common Shareholders			(618,543$)	(499,938$)	(384,023$)	(261,242$)	(2,301,592$)	(2,178,432$)	(2,064,408$)	(1,950,043$)	(1,819,230$)	(1,704,820$)	(1,591,213$)	(1,477,282$)	(1,347,277$)				(861,863$)	(741,162$)	(627,302$)	(504,987$)	(359,908$)	(237,343$)	(119,421$)	7,289$	47,308$	48,354$	41,917$	34,195$	29,804$	23,935$	16,344$	14,097$	8,202$
Additional Paid-In Capital
Retained Earnings			(162,412,117$)	(162,293,512$)	(162,177,597$)	(162,054,816$)	(161,120,166$)	(160,997,006$)	(160,874,982$)	(160,760,542$)	(160,629,729$)				(160,157,776$)				(159,672,262$)	(159,551,561$)	(159,437,701$)	(159,315,386$)	(159,170,307$)	(159,047,742$)	(158,929,820$)	(158,803,110$)	(761,752$)	(741,582$)	(735,248$)	(728,066$)	(715,214$)	(706,620$)			(647,476$)
Treasury Stock
Capital Lease Obligations

Copy Table ✓